ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Bristol-Myers Squibb and Zai Lab side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Bristol-Myers SquibbZai Lab
studies on the registry2,18432
open to participants now1569
phase 3 studies under way824
reach primary completion within a year685
programswith a study of their own in two years58+9 named only4

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBristol-Myers SquibbZai Lab
Phase 1

Bristol-Myers Squibb: 17 of its 58 programs at phase 1

  1. BMS-986454phase 1
  2. orevandrodegphase 1
  3. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1
  4. BMS-985521phase 1
  5. BMS-986485phase 1

and 12 more — sign in to see them all

29%

Zai Lab: 2 of its 4 programs at phase 1

  1. ZL-1503phase 1
  2. Anti-LRRC15 Antibody-drug Conjugate ZL-6201phase 1
50%
Phase 2

Bristol-Myers Squibb: 18 of its 58 programs at phase 2

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. delocamtenphase 2
  4. imzokitugphase 2
  5. Cyclophosphamidephase 2

and 13 more — sign in to see them all

31%
00%
Phase 3

Bristol-Myers Squibb: 16 of its 58 programs at phase 3

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. golcadomidephase 3
  5. zolacabtagene autoleucelphase 3

and 11 more — sign in to see them all

28%

Zai Lab: 2 of its 4 programs at phase 3

  1. Zocilurtatug Pelitecanphase 3
  2. elegrobartphase 3
50%
Approved, new studies

Bristol-Myers Squibb: 7 of its 58 programs at approved, new studies

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. deucravacitinibapproved, new study
  4. Nivolumabapproved, new study
  5. trospium chlorideapproved, new study

and 2 more — sign in to see them all

12%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Bristol-Myers Squibb23 readouts · 8 phase 3

Bristol-Myers Squibb, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. deucravacitinibapproved, new study · Nov 18 · NCT05946941
  2. trospiumapproved, new study · Nov 24 · NCT06585787
  3. xanomelineapproved, new study · Nov 24 · NCT06585787

Bristol-Myers Squibb, Dec ’26: 8 programs whose next study reaches primary completion, 1 in phase 3

  1. actinium AC-225 dotatatephase 3 · Dec 0 · NCT05477576
  2. trospium chlorideapproved, new study · Dec 3 · NCT07204418
  3. navlimetostatphase 3 · Dec 5 · NCT07777133
  4. delocamtenphase 2 · Dec 14 · NCT06122779
  5. golcadomidephase 3 · Dec 14 · NCT07763418

and 3 more — sign in to see them all

Bristol-Myers Squibb, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mezigdomidephase 3 · Jan 10 · NCT05519085

Bristol-Myers Squibb, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1 · Feb 0 · NCT07165132
  2. Nivolumabapproved, new study · Feb 5 · NCT06946797
  3. repotrectinibphase 3 · Feb 16 · NCT06140836
··

Bristol-Myers Squibb, May ’27: 1 program whose next study reaches primary completion

  1. elranatamabphase 2 · May 31 · NCT06988488

Bristol-Myers Squibb, Jun ’27: 3 programs whose next study reaches primary completion

  1. BMS-986533phase 1 · Jun 1 · NCT07629999
  2. BMS-986485phase 1 · Jun 8 · NCT07887763
  3. BMS-986454phase 1 · Jun 28 · NCT07171983

Bristol-Myers Squibb, Jul ’27: 1 program whose next study reaches primary completion

  1. zolacabtagene autoleucelphase 3 · Jul 15 · NCT06220201

Bristol-Myers Squibb, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. atigotatugphase 3 · Aug 17 · NCT06646276

Bristol-Myers Squibb, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. dezandrodegphase 3 · Sep 12 · NCT06764485

Bristol-Myers Squibb, Oct ’27: 1 program whose next study reaches primary completion

  1. BMS-986488phase 1 · Oct 15 · NCT06764771
Zai Lab3 readouts · 1 phase 3···

Zai Lab, Feb ’27: 1 program whose next study reaches primary completion

  1. ZL-1503phase 1 · Feb 6 · NCT07658482

Zai Lab, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. elegrobartphase 3 · Mar 14 · NCT07211776
·

Zai Lab, May ’27: 1 program whose next study reaches primary completion

  1. Zocilurtatug Pelitecanphase 3 · May 30 · NCT06179069
·····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Bristol-Myers Squibb

New programs 5

  • BMS-986548phase 2 · first study · Nov 10 · Carcinoma, Non-Small-Cell Lung
  • BMS-986485phase 1 · first study · Oct 14
  • BMS-986553phase 1 · first study · Oct 8 · Lupus Nephritis
  • RYZ711phase 2 · first study · Oct 1 · Prostatic Neoplasms
  • BMS-986527phase 1 · first study · Sep 22 · Carcinoma, Renal Cell

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Zai Lab

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionBristol-Myers SquibbZai Lab
Small Cell Lung Carcinomaboth · compare here

Bristol-Myers Squibb in Small Cell Lung Carcinoma: 5 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. atigotatugphase 3
  4. BMS-986525phase 2
  5. atigotatugphase 2

Their studies: Bristol-Myers Squibb’s studies of Small Cell Lung Carcinoma in search

Zai Lab in Small Cell Lung Carcinoma: 1 program

  1. Zocilurtatug Pelitecanphase 3

Their studies: Zai Lab’s studies of Small Cell Lung Carcinoma in search

Sarcomaboth · compare here

Bristol-Myers Squibb in Sarcoma: 1 program

  1. repotrectinibphase 3

Their studies: Bristol-Myers Squibb’s studies of Sarcoma in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Bristol-Myers Squibb 33 of 58 · Zai Lab 2 of 4 programs (18 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Bristol-Myers Squibb: 9).